TAK-360 Study for Adults With Narcolepsy Type 1
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of narcolepsy type 1 with cataplexy (sudden muscle weakness triggered by emotions)
- Your body mass index (BMI) is between 18 and 40 kg/m² (a measure of weight relative to height)
- You do not have other conditions causing extreme daytime sleepiness besides narcolepsy
- You have no serious heart problems, including heart attacks, coronary artery disease, or heart rhythm issues
- You have no history of seizures, epilepsy, or strokes in the past 5 years
- You have no cancer diagnosis in the past 5 years (with limited exceptions for certain skin cancers)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a follow-up study for people who already completed a TAK-360 trial for narcolepsy (a sleep disorder causing sudden sleep attacks) or idiopathic hypersomnia (excessive daytime sleepiness). Researchers want to see if continuing TAK-360 remains safe and effective for you.
This Phase 2/3 study tests TAK-861 in people with narcolepsy type 1 (NT1) who already completed an earlier TAK-861 trial. The goal is to see if the medicine remains safe and effective for ongoing central (brain-related) sleepiness problems.
This study tests a new medication, ALKS 2680, to see if it helps reduce daytime sleepiness and other symptoms in adults with narcolepsy type 1. It may offer a new treatment option for people with this condition.
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
This study tests whether a new medication called cleminorexton helps people with narcolepsy (a condition causing severe daytime sleepiness) sleep better and feel more alert. You would take this medication instead of your current narcolepsy drugs for several months to see if it works.
This trial tests a non-invasive brain stimulation method called temporal interference to target the hypothalamus. It aims to help reduce excessive daytime sleepiness in people with narcolepsy type 1.
Hear when a new Narcolepsy Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.